Pfizer Inc. (PFE)

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.

Pfizer experimental sickle cell drug fails phase 3 trial

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.

3 Cheap Dividend Stocks With Excellent Yields

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.

FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

FDA may pull authorization of Pfizer's Covid vaccine for children under 5

The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus.

Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?

Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

4 High-Yield Blue Chips Near 52-Week Lows: All Are Strong Buys Now

Blue-chip stocks are shares of large, well-established, financially stable companies with a history of consistent and reliable performance.

Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth in Primary Care, Specialty Care, and Oncology, but looming patent expiries and regulatory risks persist. Management's financial discipline is improving, with cost savings, debt management, and a focus on extracting value from recent M&A deals.

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

Trade Deficit Narrowed More Than Expected

Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.

Pfizer Stock Pops on Q2 Beat-and-Raise

The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.

Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Buy Pfizer Stock At $24?

Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on $14.65 billion in revenue, surpassing consensus estimates of $0.58 per share and $13.56 billion.

Pfizer raises profit forecast after Q2 earnings beat estimates

Pfizer Inc (NYSE:PFE, ETR:PFE) raised its full-year profit outlook on Tuesday after posting better-than-expected second-quarter earnings, driven by strong sales of key drugs including Comirnaty and Paxlovid. The drugmaker reported adjusted earnings of $0.78 per share, beating analysts' average estimate of $0.58, according to LSEG data.

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (August 2025)

Shares of Pfizer ( NYSE: PFE ) lost 6.50% over the past month, bringing the stock's year-to-date loss to 11.31%.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Pfizer: Earnings Meet Pressure (Rating Upgrade)

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth. Valuation appears attractive with ratios below sector medians and Wall Street seeing significant upside, yet EPS stagnation tempers enthusiasm. Despite potential for another earnings beat, a miss could trigger a selloff, while the 7.3% dividend yield offers defensive appeal amid market uncertainty.

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

2 Dividend Stocks Yielding Over 7% to Buy

PFE and CAG are two standout 7%-yielders that have relatively safe payouts. Headwinds facing both firms are tremendous, but there's already so much negativity priced in at these depths.

Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer's Comeback Is Underway

Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, and internal medicine, plus a robust R&D pipeline. Major patent expirations threaten $15B+ in annual revenue by 2028, but Pfizer is aggressively pursuing pipeline and acquisition strategies.

16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)

Graham All Star Value (GASV) strategy identifies top dividend 'dogs' offering high yield and fair pricing, using YCharts' large cap value and Ben Graham screens. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 27.55% by July 2026, with moderate risk. Sixteen of the twenty-one lowest-priced, 'safer' GASV dividend stocks are currently buyable, with dividends exceeding share price for ideal picks.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

I Am Buying 5 Blue-Chip Dividend Stocks That Have Been Crushed in 2025

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.

5 Stocks Yielding 6% and More You Can Buy Now and Forget About Forever

Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.

Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.